0000000000965596

AUTHOR

Wiebke Hollburg

showing 1 related works from this author

Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as firs…

2014

e12007 Background: B combined with chemotherapy (CT) significantly improves progression-free survival (PFS) and response rate (RR) vs CT alone in the first-line treatment of HER2-negative MBC. In a...

Response rate (survey)OncologyCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industryFirst linemedicine.medical_treatmentMedizinmedicine.diseaseMetastatic breast cancerSurgerychemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineLong term outcomesCytotoxic T cellskin and connective tissue diseasesbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct